Analysts predict that Avanos Medical Inc (NYSE:AVNS) will post sales of $180.63 million for the current quarter, according to Zacks. Three analysts have issued estimates for Avanos Medical’s earnings. The highest sales estimate is $180.80 million and the lowest is $180.50 million. Avanos Medical posted sales of $165.10 million during the same quarter last year, which suggests a positive year-over-year growth rate of 9.4%. The firm is expected to report its next earnings report on Tuesday, November 5th.
On average, analysts expect that Avanos Medical will report full-year sales of $707.57 million for the current fiscal year, with estimates ranging from $705.07 million to $709.20 million. For the next year, analysts anticipate that the company will post sales of $765.08 million, with estimates ranging from $760.90 million to $769.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Avanos Medical.
Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, August 6th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $172.20 million for the quarter, compared to analyst estimates of $172.02 million. Avanos Medical had a positive return on equity of 4.18% and a negative net margin of 3.92%. Avanos Medical’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 earnings per share.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. lifted its holdings in shares of Avanos Medical by 21.0% during the 2nd quarter. Invesco Ltd. now owns 1,637,165 shares of the company’s stock valued at $71,396,000 after buying an additional 284,234 shares during the last quarter. Stevens Capital Management LP acquired a new stake in Avanos Medical in the 2nd quarter worth approximately $452,000. Magnetar Financial LLC acquired a new stake in Avanos Medical in the 2nd quarter worth approximately $576,000. FIL Ltd lifted its holdings in Avanos Medical by 43.2% in the 1st quarter. FIL Ltd now owns 134,865 shares of the company’s stock worth $5,756,000 after purchasing an additional 40,658 shares during the last quarter. Finally, Confluence Investment Management LLC acquired a new stake in Avanos Medical in the 2nd quarter worth approximately $4,999,000. Hedge funds and other institutional investors own 94.11% of the company’s stock.
AVNS traded down $0.12 during trading on Monday, reaching $36.22. The company had a trading volume of 193,755 shares, compared to its average volume of 320,494. The firm’s 50-day simple moving average is $35.46 and its 200 day simple moving average is $40.41. The company has a market cap of $1.73 billion, a price-to-earnings ratio of 44.17 and a beta of 1.53. Avanos Medical has a 12-month low of $31.78 and a 12-month high of $64.79. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.35 and a current ratio of 3.06.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Recommended Story: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.